Bildgebung und Vorgehen bei präinvasiven Läsionen der Mamma

Zusammenfassung

Präinvasive Läsionen der Brust umfassen ein Spektrum von biologisch und klinisch heterogenen, neoplastischen Läsionen mit einem sehr unterschiedlichen Progressionspotenzial zum invasiven Brustkrebs. In dieser Übersicht werden Definitionen, diagnostische Kriterien und klinische Schlussfolgerungen zu folgenden Entitäten vorgestellt: duktales Carcinoma in situ (DCIS), atypische duktale Hyperplasie (ADH), flache epitheliale Atypie (FEA), lobuläre Neoplasie (LN).

Abstract

Precursor lesions of the breast are biologically and clinically heterogeneous neoplastic lesions with a varying risk for progression to an invasive breast cancer. This review presents definitions, diagnostic criteria and concepts for the clinical management of the following lesions: ductal carcinoma in situ (DCIS), atypical ductal hyperplasia (ADH), flat epithelial atypia (FEA), lobular neoplasia (LN).

Key words

Breast - preinvasive, ductal carcinoma in situ - atypical ductal hyperplasia - flat epithelial atypia - lobular neoplasia

Literatur

• 1 Reis-Filho J S, Lakhani S R. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions.  Breast Cancer Res. 2003;  5 313-319
• 2 Buerger H, Otterbach F, Simon R et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.  J Pathol. 1999;  187 396-402
• 3 Simpson P T, Reis-Filho J S, Gale T et al. Molecular evolution of breast cancer.  J Pathol. 2005;  205 248-254
• 4 Ellis I O. Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology.  Mod Pathol. 2010;  23 S1-S7
• 5 Simpson P TP, Gale T B, Reis-Filho J SM et al. Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression? A Morphological and Molecular Analysis.  American Journal of Surgical Pathology. 2005;  29 734-746
• 6 Buerger H, Schmidt H, Beckmann A et al. Genetic characterisation of invasive breast cancer: a comparison of CGH and PCR based multiplex microsatellite analysis.  J Clin Pathol. 2001;  54 836-840
• 7 Reis-Filho J S, Simpson P T, Gale T et al. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization.  Pathol Res Pract. 2005;  201 713-725
• 8 American College of Radiology (ACR) .Illustrated breast imaging reporting and data system (BI-RADS). Reston, VA: American College of Radiology; 2003
• 9 Page D L, Dupont W D, Rogers L W et al. Continued local recurrence of carcinoma 15 – 25 years after a diagnosis of Low-Grade-ductal carcinoma in situ of the breast treated only by biopsy.  Cancer. 1995;  76 1197-1200
• 10 Wells C A, Amendoeira I, Apostolikas N et al. Quality assurance guidelines for pathology – Cytological and histological non-operative diagnosis.. In: Perry N M, Broeders M, de Wolf C, et al., (eds) European guidelines for quality assurance in breast cancer screening and diagnosis.. Luxembourg: Office for Official Publication of the European Communities; 2006
• 11 Weigel S, Girnus R, Czwoydzinski J et al. Digital mammography screening: average glandular dose and first performance parameters.  Fortschr Röntgenstr. 2007;  179 892-895
• 12 Hartmann L C, Sellers T A, Frost M H et al. Benign breast disease and the risk of breast cancer.  N Engl J Med. 2005;  353 229-237
• 13 Degnim A C, Visscher D W, Berman H K et al. Stratification of Breast Cancer Risk in Women With Atypia: A Mayo Cohort Study.  J Clin Oncol. 2007;  25 2671-2677
• 14 Collins L C, Baer H J, Tamimi R M et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses" Health Study.  Cancer. 2007;  109 180-187
• 15 Thomssen C, Harbeck N. Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer – Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.  Breast Care (Basel). 2010;  5 345-351
• 16 Lieske B, Ravichandran D, Alvi A et al. Screen-detected breast lesions with an indeterminate (B3) core needle biopsy should be excised.  Eur J Surg Oncol. 2008;  34 1293-1298
• 17 El-Sayed M E, Rakha E A, Reed J et al. Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening.  Histopathology. 2008;  53 650-657
• 18 Weigel S, Decker T, Korsching E et al. Minimal Invasive Biopsy Results of „Uncertain Malignant Potential“ in Digital Mammography Screening: High Prevalence but also High Predictive Value for Malignancy.  Fortschr Röntgenstr. 2011;  183 743-748
• 19 Flegg K, Flaherty J, Bicknell A et al. Surgical outcomes of borderline breast lesions detected by needle biopsy in a breast screening program.  World Journal of Surgical Oncology. 2010;  8 78
• 20 Bijker N, Rutgers E J, Peterse J L et al. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10 853) investigating breast-conserving treatment for DCIS.  Eur J Surg Oncol. 2001;  27 135-140
• 21 de Mascarel I, Macgrogan G, Mathoulin-Pelissier S et al. Epithelial atypia in biopsies performed for microcalcifications. practical considerations about 2833 serially sectioned surgical biopsies with a long follow-up.  Virchows Arch. 2007;  451 1-10
• 22 Eusebi V, Feudale E, Foschini M P et al. Long-term follow-up of in situ carcinoma of the breast.  Semin Diagn Pathol. 1994;  11 223-235
• 23 Badve S, Dabbs D J, Schnitt S J et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.  Mod Pathol. 2011;  24 157-167
• 24 Abdel-Fatah T MA, Powe D G, Hodi Z et al. Morphologic and Molecular Evolutionary Pathways of Low Nuclear Grade Invasive Breast Cancers and Their Putative Precursor Lesions: Further Evidence to Support the Concept of Low Nuclear Grade Breast Neoplasia Family.  The American Journal of Surgical Pathology. 2008;  32 513-523
• 25 Kunju L P, Kleer C G. Significance of flat epithelial atypia on mammotome core needle biopsy: should it be excised?.  Human Pathology. 2007;  38 35-41
• 26 Weigel S, Decker T, Korsching E et al. Calcifications in Digital Mammographic Screening: Improvement of Early Detection of Invasive Breast Cancers?.  Radiology. 2010;  255 738-745
• 27 Foote F W, Steward F W. Lobular carcinoma in situ.  American Journal of Pathology. 1941;  17 491-496
• 28 Haagensen C D, Lane N, Lattes R et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast.  Cancer. 1978;  42 737-769
• 29 Tavassoli F A, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC-Press. Classification of Tumours. World Health Organisation; 2003
• 30 Lakhani S R, Audretsch W, Cleton-Jensen A M et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?.  European Journal of Cancer. 2006;  42 2205-2211
• 31 Bratthauer G L, Tavassoli F A. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications.  Virchows Arch. 2002;  440 134-138
• 32 Hanby A M, Hughes T A. In situ and invasive lobular neoplasia of the breast.  Histopathology. 2008;  52 58-66
• 33 Georgian-Smith D, Lawton T J. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation.  AJR Am J Roentgenol. 2001;  176 1255-1259
• 34 Page D L, Kidd T E, Dupont W D et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease.  Hum Pathol. 1991;  22 1232-1239
• 35 Akashi-Tanaka S, Fukutomi T, Nanasawa T et al. Treatment of noninvasive carcinoma: fifteen-year results at the National Cancer Center Hospital in Tokyo.  Breast Cancer. 2000;  7 341-344
• 36 Li C I, Daling J R, Malone K E. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.  Cancer Epidemiol Biomarkers Prev. 2005;  14 1008-1011
• 37 Frykberg E R. Lobular Carcinoma In Situ of the Breast.  Breast J. 1999;  5 296-303
• 38 Ottesen G L, Graversen H P, Blichert-Toft M et al. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group.  Am J Surg Pathol. 1993;  17 14-21
• 39 Ottesen G L, Graversen H P, Blichert-Toft M et al. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.  Breast Cancer Res Treat. 2000;  62 197-210
• 40 Goldstein N S, Kestin L L, Vicini F A. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.  Cancer. 2001;  92 738-747
• 41 Page D L, Schuyler P A, Dupont W D et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study.  Lancet. 2003;  361 125-129
• 42 Hussain M, Cunnick G H. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast – a review.  European Journal of Surgical Oncology. 2011;  37 279-289
• 43 Ciocca R M, Li T, Freedman G M et al. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.  Ann Surg Oncol. 2008;  15 2263-2271
• 44 Deutsche Gesellschaft für Senologie, Deutsche Krebsgesellschaft .Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland.. München: Zuckschwerdt; 2008